A Research Agenda for Malaria Eradication: Vaccines

English version České info

Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. We introduce the concept of “vaccines that interrupt malaria transmission” (VIMT), which includes not only “classical” transmission-blocking vaccines that target the sexual and mosquito stages but also pre-erythrocytic and asexual stage vaccines that have an effect on transmission. VIMT may also include vaccines that target the vector to disrupt parasite development in the mosquito. Importantly, if eradication is to be achieved, malaria vaccine development efforts will need to target other malaria parasite species, especially Plasmodium vivax, where novel therapeutic vaccines against hypnozoites or preventive vaccines with effect against multiple stages could have enormous impact. A target product profile (TPP) for VIMT is proposed and a research agenda to address current knowledge gaps and develop tools necessary for design and development of VIMT is presented.

Vyšlo v časopise: A Research Agenda for Malaria Eradication: Vaccines. PLoS Med 8(1): e32767. doi:10.1371/journal.pmed.1000398
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000398

Souhrn

Zdroje

1. HendersonDA

1987 Principles and lessons from the smallpox eradication programme. Bull World Health Organ 65 535 546

2. JohnJ

2009 Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines Jan 8 5 8

3. MossWJ

GriffinDE

2006 Global measles elimination. Nat Rev Microbiol 12 900 908

4. BremanJG

de QuadrosCA

DowdleWR

FoegeWH

HendersonDA

2011 The role of research in viral disease eradication and elimination programs: Lessons for malaria eradication. PLoS Med 8 e1000405 doi:10.1371/journal.pmed.1000405

5. RoperMH

VandelaerJH

GasseFL

2007 Maternal and neonatal tetanus. Lancet 370 1947 1959

6. AdegbolaRA

SeckaO

LahaiG

Lloyd-EvansN

NjieA

2005 Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: A prospective study. Lancet 366 144 150

7. Malaria Vaccine Technology Roadmap Final Report 2006 Available: http://www.malariavaccineroadmap.net

8. WHO 2000 Malaria transmission blocking vaccines: An ideal public good. Geneva: World Health Organization. Available: http://www.who.int/vaccine_research/feuille_1_4-1pdf

9. CarterR

2001 Transmission blocking malaria vaccines. Vaccine 19 2309 2314

10. RobertsDR

ManguinS

MoudhetJ

2000 DDT house spraying and re-emerging malaria. Lancet 356 330 332

11. O'MearaWP

BejonP

MwangiTW

OkiroEA

PeshuN

2008 Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372 1555 1562

12. CeesaySJ

Casals-PascualC

ErskineJ

AnyaSE

DuahNO

2008 Changes in malaria indices between 1999 and 2007 in The Gambia: A retrospective analysis. Lancet 372 1545 1554

13. MendisK

SinaBJ

MarchesiniP

CarterR

2001 The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 97 106

14. KocharDK

DasA

KocharSK

SaxenaV

SirohiP

2009 Severe Plasmodium vivax malaria: A report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg Feb 80 194 198

15. KocharDK

SaxenaV

SinghN

KocharSK

KumarSV

2005 Plasmodium vivax malaria. Emerg Infect Dis Jan 11 132 134

16. PriceRN

TjitraE

GuerraCA

YeungS

WhiteNJ

2007 Vivax malaria: Neglected and not benign. Am J Trop Med Hyg 77 79 87

17. PriceRN

DouglasNM

AnsteyNM

2009 New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22 430 435

18. The malERA Consultative Group on Basic Science and Enabling Technologies 2011 A research agenda for malaria eradication: Basic science and enabling technologies. PLoS Med 8 e1000399 doi:10.1371/journal.pmed.1000399

19. LeeKS

Cox-SinghJ

BrookeG

MatusopA

SinghB

2009 Plasmodium knowlesi from archival blood films: Further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo. Int J Parasitol 9 1125 1128

20. Cox-SinghJ

DavisTM

LeeKS

ShamsulSS

MatusopA

2008 Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46 165 171

21. DixonMW

ThompsonJ

GardinerDL

TrenholmeKR

2008 Sex in Plasmodium: A sign of commitment. Trends Parasitol 24 168 175

22. The malERA Consultative Group on Drugs 2011 A research agenda for malaria eradication: Drugs. PLoS Med 8 e1000402 doi:10.1371/journal.pmed.1000402

23. MalkinEM

DurbinAP

DiemertDJ

SattabongkotJ

WuY

2005 Phase 1 vaccine trial of Pvs25H: A transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 3131 3138

24. WuY

EllisRD

ShafferD

FontesE

MalkinEM

2008 Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3 e2636 doi:10.1371/journal.pone.0002636

25. OutchkourovNS

RoeffenW

KaanA

JansenJ

LutyA

2008 Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A 105 4301 4305

26. ChowdhuryDR

AngovE

KariukiT

KumarN

2009 A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 4 e6352 doi:10.1371/journal.pone.0006352

27. AlonsoPL

SacarlalJ

AponteJJ

LeachA

MaceteE

2004 Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364 1411 1420

28. AlonsoPL

SacarlalJ

AponteJJ

LeachA

MaceteE

2005 Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366 2012 2018

29. HoffmanSL

BillingsleyPF

JamesE

RichmanA

LoyevskyM

2010 Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6 97 106

30. PinderM

MoorthyVS

AkanmoriBD

GentonB

BrownGV

2010 Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Vaccine 6 97 106

31. DinglasanRR

KalumeDE

KanzokSM

GhoshAK

MuratovaO

2007 Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci U S A 104 13461 13466

32. The malERA Consultative Group on Vector Control 2011 A research agenda for malaria eradication: Vector control. PLoS 8 e1000401 doi:10.1371/journal.pmed.1000401

33. MotaMM

HafallaJC

RodriguezA

2002 Migration through host cells activates Plasmodium sporozoites for infection. Nat Med 8 1318 1322

34. SultanAA

ThathyV

FrevertU

RobsonKJ

CrisantiA

1997 TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 90 511 522

35. CeramiC

FrevertU

SinnisP

TakacsB

ClavijoP

1992 The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70 1021 1033

36. TewariR

SpaccapeloR

BistoniF

HolderAA

Crisanti A. 2002 Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J Biol Chem 277 47613 47618

37. WengelnikK

SpaccapeloR

NaitzaS

RobsonKJ

JanseCJ

1999 The A-domain and the thrombospondin-related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands. EMBO J 18 5195 5204

38. NarumDL

HaynesJD

FuhrmannS

MochK

LiangH

2000 Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun 68 1964 1966

39. PandeyKC

SinghS

PattnaikP

PillaiCR

PillaiU

2002 Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol 123 23 33

40. PattnaikP

ShakriAR

SinghS

GoelS

MukherjeeP

2007 Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 25 806 813

41. SimBK

ChitnisCE

WasniowskaK

HadleyTJ

MillerLH

1994 Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264 1941 1944

42. GrimbergBT

UdomsangpetchR

XainliJ

McHenryA

PanichakulT

2007 Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 4 e337 doi:10.1371/journal.pmed.0040337

43. GaoX

YeoKP

AwSS

KussC

IyerJK

2008 Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites. PLoS Pathog 4 e1000104 doi:10.1371/journal.ppat.1000104

44. DraperSJ

MooreAC

GoodmanAL

LongCA

HolderAA

2008 Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14 819 821

45. TakalaSL

PloweCV

2009 Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’. Parasite Immunol 31 560 573

46. The malERA Consultative Group on Cross Cutting Issues for Eradication 2011 A research agenda for malaria eradication: Cross cutting issues for eradication. PLoS 8 e1000404 doi:10.1371/journal.pmed.1000404

47. The malERA Consultative Group on Basic Monitoring, Evaluation, and Surveillance 2011 A research agenda for malaria eradication: Monitoring, evaluation, and surveillance. PLoS 8 e1000400 doi:10.1371/journal.pmed.1000400

48. BousemaJT

SchneiderP

GouagnaLC

DrakeleyCJ

TostmannA

2006 Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 193 1151 1159

49. van der KolkM

De VlasSJ

SaulA

van de Vegte-BolmerM

ElingWM

2005 Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 130 13 22

50. WHO 1997 Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infection. Geneva WHO

51. PennyMA

MaireN

StuderA

SchapiraA

SmithTA

2008 What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One 3 e3193 doi:10.1371/journal.pone.0003193

52. The malERA Consultative Group on Modeling 2011 A research agenda for malaria eradication: Modeling. PLoS 8 e1000403 doi:10.1371/journal.pmed.1000403

53. The malERA Consultative Group on Diagnoses and Diagnostics 2011 A research agenda for malaria eradication: Diagnoses and diagnostics. PLoS 8 e1000396 doi:10.1371/journal.pmed.1000396

54. World Health Organization 2000 Making use of vaccine vial monitors. Flexible vaccine management for polio. Geneva: World Health Organization Available: www.who.int/vaccines-documents/DocsPDF00/www516.pdf

55. World Health Organization 2006 Procedures for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. Geneva: World Health Organization Available: www.who.int/vaccines-documents/DocsPDF06/812.pdf